Compare ACADIA Pharmaceuticals Inc. (ACAD) vs BlackBerry Limited (BB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs BlackBerry Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while BlackBerry Limited trades at $10.88 (market cap $6.49B). The key difference: BlackBerry Limited is the larger of the two by market cap. Which is the better fit depends on your goals.
| ACAD | BB | |
|---|---|---|
Market Cap | $4.49B | $6.49B |
Sector | Health | Technology |
52-Week High | $28.06 | $12.81 |
52-Week Low | $20.06 | $3.15 |
Enterprise Value | $3.69B | $6.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BlackBerry (BB) trades at $11.10, down 3.56% on the day but remains in a strong uptrend, having more than tripled year-to-date. The stock is technically bullish with recent earnings beats and improved guidance fueling optimism. Revenue growth is returning, with Q1 2026 results showing a profit turnaround, though valuation multiples remain elevated. Positive sentiment is driven by QNX software growth and the launch of leveraged ETFs tied to the stock.
Outlook is cautiously optimistic as execution on QNX and cybersecurity growth must justify high valuations. Key risks include competitive pressures and the need to sustain profitability. Analysts are mostly neutral with a consensus price target of $10.50, suggesting limited near-term upside from current levels amid rich pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →
